Stem Cell–Based Therapy for Coronavirus Disease 2019
Robert Chunhua Zhao
Abstract
The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. In this commentary, we offer an alternative promising therapy for COVID-19, that is, mesenchymal stem cell transplantation.
Topics & Concepts
BiologyCoronavirusCoronavirus disease 2019 (COVID-19)TransplantationVirologyDiseasePublic healthPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)China2019-20 coronavirus outbreakMesenchymal stem cellInfectious disease (medical specialty)Intensive care medicineInternal medicineOutbreakPathologyMedicineLawCell biologyPolitical scienceMesenchymal stem cell researchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19